Pediatric Biopharmaceutical Classification System: Using Age-Appropriate Initial Gastric Volume

Area of Science:

• Pharmacokinetics and Drug Development
• Pediatric Pharmacology
• Biopharmaceutical Sciences

Background:

• Optimizing pediatric oral formulations presents significant challenges.
• The biopharmaceutical classification system (BCS) aids adult oral drug formulation but lacks comprehensive pediatric adaptation.
• Existing biowaiver criteria may not be universally applicable to pediatric populations.

Purpose of the Study:

• To provisionally classify drugs from the WHO Essential Medicines List for Children using an age-appropriate BCS.
• To investigate age-related shifts in drug solubility classes within pediatric subpopulations.
• To highlight knowledge gaps in pediatric biopharmaceutics.

Main Methods:

• Classified 38 orally administered drugs from the WHO Essential Medicines List for Children.
• Calculated dose numbers using age-appropriate gastric volumes (neonates to adults).
• Applied British National Formulary age-specific dosing recommendations.

Main Results:

• Identified age-dependent shifts in BCS solubility classes for several drugs, including amoxicillin, cephalexin, chloramphenicol, diazepam, doxycycline, erythromycin, phenobarbital, prednisolone, and trimethoprim.
• Demonstrated that solubility classifications can change significantly in pediatric subpopulations compared to adults.
• Highlighted the need for age-specific biopharmaceutical considerations.

Conclusions:

• An age-appropriate BCS is essential for pediatric drug formulation development.
• Current biowaiver strategies require re-evaluation for pediatric use.
• Further research is needed to address knowledge gaps in pediatric biopharmaceutics.